To the Editor—Koullias et al [1] argue against testing for integrase strand transfer inhibitor (INSTI) resistance in newly diagnosed patients with human immunodeficiency virus (HIV) prior to initiation of antiretroviral therapy (ART). The authors’ position is based on the low prevalence of primary INSTI resistance and the preserved efficacy of dolutegravir despite certain resistance mutations in integrase selected by other INSTI [2]. One point omitted from their position is the possibility of false positive test results. Here we describe a recently encountered instance of a false positive INSTI resistance genotype.

中文翻译：

---

初治患者反对测试INSTI抵抗力的争论

致编辑-Koullias等[1]反对在开始抗逆转录病毒治疗（ART）之前对新诊断的人免疫缺陷病毒（HIV）患者进行整合酶链转移抑制剂（INSTI）抗性测试。作者的立场是基于原发性INSTI耐药性较低和dolutegravir的疗效得以维持，尽管其他INSTI选择了整合酶中的某些耐药性突变[2]。从他们的位置上忽略的一点是可能会产生错误的阳性测试结果。在这里，我们描述了一个假阳性的INSTI耐药基因型的最近遇到的实例。